ClinicalTrials.Veeva

Menu

The Evolution of Systemic Microvascular Reactivity in Heart Transplant Patients

N

National Institute of Cardiology, Laranjeiras, Brazil

Status

Enrolling

Conditions

Heart Transplantation

Treatments

Diagnostic Test: skin microvascular reactivity

Study type

Observational

Funder types

Other

Identifiers

NCT05729009
45581521.0.0000.5272

Details and patient eligibility

About

The evolution of systemic microvascular reactivity may aid in the comprehension of cardiovascular physiology in heart transplantation patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients.

Full description

Introduction: Systemic microvascular reactivity (MR) is an essential component of cardiovascular physiology, being studied through non-invasive techniques in readily accessible body regions, such as the skin surface. Heart transplant (HT) is a treatment considered to selected patients, with advanced heart failure. The main cause of long-term mortality after HT is graft vascular disease (GVD), a condition which starts with endothelial dysfunction. To know the evolution of systemic MR in patients subjected to HT can help to find prognostic factors. Objective: The present study aims to perform the prospective evaluation of systemic MR in adult patients, before and two years after HT, at a quaternary hospital, correlating the findings with clinical variables. Methods: Systemic MR will be evaluated in the skin of the forearm using laser speckle contrast imaging with acetylcholine (ACh) iontophoresis, followed by postocclusive reactive hyperemia (PORH), before and after HT. Measurements will be correlated to patient clinical profile, hemodynamic and echocardiographic data. Expected results: The evolution of systemic MR may aid in the comprehension of cardiovascular physiology in HT patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients.

Enrollment

31 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • capability to understand the objectives of the research and to fulfill the Term of Consent

Exclusion criteria

  • Pregnancy, acute infection diagnosis, use of circulatory assistance devices

Trial design

31 participants in 1 patient group

heart transplantation
Treatment:
Diagnostic Test: skin microvascular reactivity

Trial contacts and locations

1

Loading...

Central trial contact

Eduardo Tibirica Tibirica, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems